References
1. McCarthy BJ, Shibui S, Kayama T, et al. Primary CNS germ cell tumors
in Japan and the United States: An analysis of 4 tumor registries.Neuro Oncol . 2012;14(9):1194-1200.
2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health
Organization Classification of Tumors of the Central Nervous System: a
summary. Acta Neuropathol . 2016;131(6):803-820.
3. Kong Z, Wang Y, Dai C, Yao Y, Ma W, Wang Y. Central Nervous System
Germ Cell Tumors: A Review of the Literature. J Child Neurol .
2018;33(9):610-620.
4. Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ
cell tumors: A clinical analysis of 153 histologically verified cases.J Neurosurg . 1997;86(3):446-455.
5. Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with
intracranial non-germinomatous germ cell tumors—lessons from the
SIOP-CNS-GCT-96 trial. Neuro Oncol . 2017;19(12):1661-1672.
6. Calaminus G, Kortmann R, Worch J, et al. SIOP CNS GCT 96: Final
report of outcome of a prospective, multinational nonrandomized trial
for children and adults with intracranial germinoma, comparing
craniospinal irradiation alone with chemotherapy followed by focal
primary site irradiation for patients with localized disease.Neuro Oncol . 2013;15(6):788-796.
7. Ogawa K, Shikama N, Toita T, et al. Long-term results of radiotherapy
for intracranial germinoma: A multi-institutional retrospective review
of 126 patients. Int J Radiat Oncol Biol Phys .
2004;58(3):705-713.
8. Modak S, Gardner S, Dunkel IJ, et al. Thiotepa-based high-dose
chemotherapy with autologous stem-cell rescue in patients with recurrent
or progressive CNS germ cell tumors. J Clin Oncol .
2004;22(10):1934-1943.
9. Bouffet E, Baranzelli MC, Patte C, et al. Combined treatment modality
for intracranial germinomas: Results of a multicentre SFOP experience.Br J Cancer . 1999;79(7-8):1199-1204.
10. da Silva NS, Cappellano AM, Diez B, et al. Primary chemotherapy for
intracranial germ cell tumors: Results of the third international CNS
germ cell tumor study. Pediatr Blood Cancer . 2010;54(3):377-383.
11. Murray MJ, Bailey S, Heinemann K, et al. Treatment and outcomes of
UK and German patients with relapsed intracranial germ cell tumors
following uniform first-line therapy. Int J Cancer .
2017;141(3):621-635. doi:10.1002/ijc.30755
12. Bouffet E. The role of myeloablative chemotherapy with autologous
hematopoietic cell rescue in central nervous system germ cell tumors.Pediatr Blood Cancer . 2010;54(4):644-646.
13. Callec L, Lardy-Cleaud A, Guerrini-Rousseau L, et al. Relapsing
intracranial germ cell tumours warrant retreatment. Eur J Cancer .
2020;136:186-194.
14. EA E, P T, J B, et al. New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer .
2009;45(2):228-247.
15. Murray MJ, Bailey S, Heinemann K, et al. Treatment and outcomes of
UK and German patients with relapsed intracranial germ cell tumors
following uniform first-line therapy. Int J Cancer .
2017;141(3):621-635.
16. Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M,
Nicholson JC. Consensus on the management of intracranial germ-cell
tumours. Lancet Oncol . 2015;16(9):e470-e477.
17. Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with
intracranial non-germinomatous germ cell tumors—lessons from the
SIOP-CNS-GCT-96 trial. Neuro Oncol . 2017;19(12):1661-1672.
18. Wilson S. GUIDANCE FOR THE MANAGEMENT OF PATIENTS WITH
RELAPSED INTRACRANIAL GERM CELL TUMOURS AFTER INITIAL PRIMARY TREATMENT
WITH RADIOTHERAPY AND CHEMOTHERAPY On Behalf of the CCLG Germ Cell
Tumour Special Interest Group-Guidance Lead Guidance Author .; 2021.